Latest News

“Too often, when someone is diagnosed with a rare cancer, their healthcare team has never treated it before — sometimes they haven’t even heard of it,” said RCA chief executive Christine Cockburn.

This week on the Dispatched Podcast, we unpack the erosion of trust in health decision-making, from Brett Sutton’s COVID-19 admissions to MSAC’s rejection of Pompe disease screening. They contrast Australia’s insular system with New Zealand’s Pharmac reforms and assess the Trump administration’s MFN pricing policy and new tariff.

Associate Professor Ruth Colagiuri, JAFA’s Founder and Director, said the award was a tribute to families, volunteers, donors, clinicians and youth advocates who have contributed to its mission.

Ed Hollywood, General Manager of Boehringer Ingelheim ANZ, said, “We will have a stronger health system if we embed lived experience in how we design, evaluate, and fund healthcare.”

Surely the first reaction of the Albanese Government, its ministers, and the supporting officials to the Trump administration’s ‘Most Favored Nation’ pharmaceutical pricing policy will be to wait and see.

The TGA has launched a consultation on whether paper Product Information leaflets should remain a mandatory inclusion in the packaging of injectable medicines that are self-administered by patients or carers.

uniQure has announced that its experimental gene therapy, AMT-130, appeared to slow the progression of Huntington’s disease over three years in patients with early-stage disease.

Australia’s life sciences community will gather in Melbourne next month for the AusBiotech International Conference, with confirmation that Senator Tim Ayres, the Federal Minister for Industry and Innovation and Minister for Science, will address delegates during the nation’s biggest week in biotech.

Recce Pharmaceuticals (ASX:RCE) has taken a significant step forward in its bid to deliver the world’s first dedicated treatment for diabetic foot infections, with patient dosing now underway in its Phase 3 registrational clinical trial in Indonesia.

On World Pharmacists Day, new research has revealed that millions of Australians are missing out on faster, more accessible healthcare simply because they do not realise the full extent of services available at their local pharmacy.

Lumos Diagnostics (ASX:LDX) has reported encouraging real-world data from the use of its FebriDx point-of-care test across general practice, urgent care, and Acute Respiratory Infection hubs in the UK, showing the device can reduce unnecessary antibiotic use, improve patient satisfaction, and ease health system costs.

Eisai and Biogen confirmed that the Therapeutic Goods Administration has registered the medicine for use in adults with mild cognitive impairment or mild dementia due to Alzheimer’s disease who are APOE4 non-carriers or heterozygotes.